Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with comparator 5‐aminosalicylic acid formulation (moderate certainty).
1 finding from 1 review
Relapse during intervention defined as admission to inpatient therapeutic care, remain wasted, and dropouts during intervention period · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
Standard ready‐to‐use therapeutic food (RUTF) leads to lower relapse during intervention defined as admission to inpatient… compared with RUTF using an alternative formulation (high certainty).
1 finding from 1 review
Mortality during intervention · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
Standard ready‐to‐use therapeutic food (RUTF) showed no clear difference in mortality during intervention compared with RUTF using an alternative formulation (moderate certainty).
1 finding from 1 review
Rate of weight gain (g/kg/day) · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
1 finding from 1 review
Recovery during intervention defined as weight gain ≥ 15% in relation to baseline weight, absence of complications and oedema, and MUAC > 110 mm in 2 studies; MUAC > 12.4 cm without oedema in 1 study; WHZ ≥ 80% for two consecutive visits in 1 stud... · children aged 6 months‐5 years with SAM (and mixed HIV comorbidity), some of whom had been stabilised as inpatients pre‐trial
Standard ready‐to‐use therapeutic food (RUTF) showed no clear difference in recovery during intervention defined as weight gain ≥ 15% in… compared with RUTF using an alternative formulation (high certainty).
1 finding from 1 review
Number of episodes of regurgitation or vomiting per day · Formula‐fed healthy term infants up to 6 months of age with gastro‐oesophageal reflux
1 finding from 1 review
Proportion of infants without regurgitation or vomiting at the end of intervention period (asymptomatic infants) · Formula‐fed healthy term infants up to 6 months of age with gastro‐oesophageal reflux
Feed thickener may leads to higher proportion of infants without regurgitation or vomiting at the end… compared with control (low certainty).
1 finding from 1 review
Reflux index (percentage of time pH < 4) · Formula‐fed healthy term infants up to 6 months of age with gastro‐oesophageal reflux
1 finding from 1 review
Number of reflux episodes lasting > 5 minutes · Formula‐fed healthy term infants up to 6 months of age with gastro‐oesophageal reflux
1 finding from 1 review
Duration of longest reflux episode · Formula‐fed healthy term infants up to 6 months of age with gastro‐oesophageal reflux
1 finding from 1 review
Diarrhoea · Formula‐fed healthy term infants up to 6 months of age with gastro‐oesophageal reflux
1 finding from 1 review
Intervention not reported
Treatment failure day‐28 PCR‐adjusted(PP population) · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in treatment failure day‐28 PCR‐adjusted(PP population) (low certainty).
1 finding from 1 review
Intervention not reported
Treatment failureday‐28 PCR‐adjusted(ITT population) · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in treatment failureday‐28 PCR‐adjusted(ITT population) (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Drug‐related adverse events · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention probably leads to lower drug‐related adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Drug‐related vomiting · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in drug‐related vomiting (low certainty).
1 finding from 1 review